Komori
Annual Securities Report7096StemCell InstituteServices

Annual Securities Report — FY2025

What StemCell Institute reported for the period from 2025-04-01 to 2026-03-31.

How much it says
67Detailed
What moved here
17named for the first time
Its own wording
69terms
Which filing this is
16/ 16newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

The Securities Report for the 27th fiscal year, covering 1 April 2025 to 31 March 2026, was filed. The company transitioned to consolidated financial reporting, presenting its operating performance, financial position and cash flows, including net sales of ¥2,811.344 million. The filing also updates disclosures on the penetration of HOPECELL as part of the cell-banking business, the launch of a Southeast Asian base in Singapore, related R&D and capital expenditure, and its licensing, risk-management and governance frameworks.

Komori's summary of this document, not the document's own words.
67Detailed
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 33 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
Change intensity
37
Thin
Strategic shift
94
Very detailed
Capital movements
75
Very detailed
Disclosure Gaps
100
Very detailed
Future commitments
68
Detailed
Change in Risk
69
Detailed
Financial and Capital Policy
53
Typical
Product Portfolio
55
Typical
Technology Position
32
Thin
Confidence in Strategic Bets
R&D spend30百万円Money spent making new things.
Cash left over-7億円Cash from the business, less what went into equipment.
Spent on equipment5億円Plants, machines — things meant to last.
Employees120Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
StemCell Institute — FY2025 | Komori